|1.||Li, Philip Kam-Tao: 2 articles (07/2010 - 01/2006)|
|2.||Szeto, Cheuk Chun: 2 articles (07/2010 - 01/2006)|
|3.||Chow, Kai Ming: 2 articles (07/2010 - 01/2006)|
|4.||Leung, Chi Bon: 2 articles (07/2010 - 01/2006)|
|5.||Van Damme, Pierre: 2 articles (04/2007 - 06/2006)|
|6.||van Hattum, J: 2 articles (03/2002 - 11/2001)|
|7.||Leroux-Roels, Geert: 1 article (06/2015)|
|8.||Curran, Desmond: 1 article (06/2015)|
|9.||De Ridder, Marc: 1 article (06/2015)|
|10.||Janssen, Julia M: 1 article (02/2015)|
06/01/1996 - "Thus, hepatitis B vaccination (Engerix-B, SmithKline Beecham Biologicals) can be used effectively in PCM for mass vaccination in developing communities."
01/01/2010 - "In this clinical trial study, 62 healthy adult volunteers were randomly assigned to receive either the Engerix-B or the Hepavax-Gene hepatitis B recombinant vaccine. "
06/22/2015 - "Response to publications by Heyward W et al. and Kuan R et al.: Clinical and cost-effectiveness analyses, respectively, of hepatitis B vaccination-Heplisav™ compared with Engerix-B(®) vaccine in adults."
07/01/2010 - "Seroconversion [hepatitis B surface antibody (anti-HBs) level > or =10 IU/l 3 months after completion of the third dose] occurred in 78.6% of patients after 40-microg Engerix-B dosage treatment versus 62.2% for those receiving 80-microg Engerix-B treatment (P = 0.11). "
12/01/2003 - "The subjects were administered 3 doses of recombinant Hepatitis B-(Engerix B) vaccine at 0, 1 and 6 months duration using 20 micrograms of vaccine per dose. "
06/01/1996 - "Engerix-B vaccine was safe and immunogenic when given with other routine childhood immunizations at 2, 4 and 6 months of age, and should provide long-term protection against hepatitis B virus infection."
11/03/2007 - "There were four deaths during this same follow-up period; all of them after the active detection of infection period had finished at study month 6 (two in RTSS/AS02D group and two in the Engerix-B group). "
09/01/1998 - "With regard to the alarmingly high prevalence of this infection in their haemodialyzation centre the authors analyzed retrospectively the effectiveness of the most successful preventive measure--active immunization--in 84 patients immunized with Engerix B according to the protocol recommended for haemodialyses. "
02/01/1994 - "[Engerix B vaccine in prophylaxis of hepatitis B virus infection in children with diabetes]."
08/20/2013 - "The objective of this analysis was to evaluate the cost-effectiveness of vaccination with HEPLISAV vs. Engerix-B(®) to prevent hepatitis B infection in select populations. "
|3.||Hepatitis A (Hepatitis, Infectious)
09/01/2006 - "Study shows that combination vaccine against hepatitis A and B (Twinrix) at least non inferior in terms of immunogenicity, safety and tolerability to monovalent vaccines (Havrix and Engerix-B), were registered in Russia."
09/14/2001 - "A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults."
04/01/2011 - "HIV-infected youth, aged 12 to younger than 25 years, were randomly assigned to one of three treatment arms: Arm 1: Engerix B, 20 μg HBsAg; Arm 2: Engerix B (GlaxoSmithKline, Rixensart, Belgium), 40 μg; and Arm 3: Twinrix (GlaxoSmithKline, Rixensart, Belgium), 20 μg HBsAg combined with 720 ELU hepatitis A antigen. "
09/01/2006 - "Immunogenicity of studied combination vaccine Twinrix was evaluated in comparison with two simultaneously administered monovalent vaccines against hepatitis A and B (Havrix and Engerix-B) in 200 healthy subjects aged 18-40, which were seronegative to hepatitis A and B. "
01/01/1999 - "SmithKline Beecham Biologicals produces two vaccines against hepatitis: hepatitis B (Engerix-B) introduced in 1986 and hepatitis A (Havrix) introduced in 1991. "
|4.||Chronic Kidney Failure (Chronic Renal Failure)
08/20/2013 - "In the patients with chronic or end stage kidney disease, HEPLISAV was the dominant option and was cost-saving compared with Engerix-B. "
01/01/2006 - "Our results suggest the potential for the three-dose schedule of recombinant vaccine Engerix-B 80 microg to prolong the immune response among ESRD population."
01/01/2006 - "Immunization with Engerix-B 80-microg dose is estimated to prevent one extra ESRD subject who would lose seroprotective anti-HBs level at 1 year for every 5.6 patients treated (number needed to treat to benefit, 5.6 (95% CI 5.4-5.8)). "
07/14/2005 - "We compared seroconversion rates in 121 predialysis patients with moderate chronic renal failure using either 40 or 20 microg of Engerix B recombinant hepatitis B vaccine administered at 0, 1 and 6 months. "
10/01/2005 - "Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease."
|5.||beta-Thalassemia (Cooley's Anemia)
05/01/2003 - "Seventy patients with beta-thalassemia (median age 6 years; range 8 months to 22 years; 49 male), who had received seven to 623 (median 61) units of blood each and three doses (10/20 micro g) of HBV vaccine (Engerix B) before presentation to us, were included in the study; 50 of the 70 patients had received transfusions prior to vaccination. "
|1.||Hepatitis B Vaccines (Hepatitis B Vaccine)
|3.||Hepatitis B Surface Antigens (HBsAg)
|4.||Hepatitis A Vaccines (Hepatitis A Vaccine)
|1.||Renal Dialysis (Hemodialysis)
|2.||Highly Active Antiretroviral Therapy (HAART)
|3.||Continuous Ambulatory Peritoneal Dialysis (CAPD)